Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-041 · 2 trials · 3 indications
BACS is a reliable and sensitive measure of cognitive function in schizophrenia. The BACS consists of items across six subtests: Verbal Memory, Digit Sequencing, Token Motor, Verbal Fluency, Symbol Coding, and Tower of London. The subtest scale scores were used to compute a composite BACS t-score of 50 (20) is the mean (standard deviation) of a relevant index population. Higher values indicate better performance. Bayesian normal linear model was used for analysis.
Blood-oxygen-level-dependent imaging, or BOLD-contrast imaging, is a method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time. The MID task is a reward anticipation paradigm that robustly engages the VS, a key area associated with coding incentive reward. Dysfunctional processing of reward information is associated with motivational impairments in schizophrenia. Motivational impairment is a key aspect of negative symptoms, and has been associated with reduced activity in the VS. Any change in BOLD signal that comes in fMRI is reported.
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug or due to a study procedure; it did not necessarily have to have a causal relationship with this treatment. A TEAE was defined as an AE that occurred or worsened after receiving the first dose of study drug and within 6 weeks after the last dose of study drug. A TEAE may also have been a pre-treatment AE or a concurrent medical condition diagnosed before the date of first dose of study drug that increased in severity after the start of dosing.
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug or due to a study procedure; it did not necessarily have to have a causal relationship with this treatment.
Clinical laboratory tests included serum chemistry, hematology and urinalysis. MAV criteria:Alanine aminotransferase(U/L) \>3 x upper limit of normal(ULN);albumin\<2.5g/dL,\<25g/L;alkaline phosphatase (U/L)\>3 x ULN; aspartate aminotransferase (U/L)\>3 x ULN;bicarbonate\<8.0 mmol/L; bilirubin\>2.0mg/dL, \>34.2 μmol/L;blood urea nitrogen\>30 mg/dL,\>10.7mmol/L;calcium\<7.0 mg/dL,\<1.75 mmol/L, \>11.5 mg/dL,\>2.88 mmol/L;chloride\<75 mmol/L,\>126 mmol/L;creatine kinase(U/L) \>5 xULN; creatinine\>2.0 mg/dL,\>177μmol/L;direct bilirubin\>2 x ULN;gamma glutamyl transferase (U/L)\>3 x ULN;glucose\<50 mg/dL,\<2.8 mmol/L,\>350 mg/dL,\>19.4 mmol/L;potassium\<3.0 mmol/L \>6.0 mmol/L; protein(g/L)\<0.8 x LLN \>1.2 x ULN;sodium\<130mmol/L \>150mmol/L;erythrocytes(10\^12erythrocytes/L) \<0.8 x LLN,\>1.2 x ULN;hematocrit(fraction of 1)\<0.8 x LLN,\>1.2xULN;hemoglobin(g/L)\<0.8 x LLN\>1.2 x ULN;leukocytes(10\^9 leukocytes/L)\<0.5 x LLN \>1.5 x ULN;platelets(10\^9 platelets/L)\<75-\>600. Categories with at least one participant are reported.
Vital signs included oral body temperature measurement, supine and standing blood pressure, respiration rate, and pulse. Pulse and blood pressure was measured after 5 minutes supine and again at 1 and 3 minutes after standing. The markedly abnormal value (MAV) criteria for vital signs included systolic blood pressure \< 85 mmHg, \> 180 mmHg; diastolic blood pressure \< 50 mmHg, \> 110 mmHg; pulse \< 50 beats/min, \> 120 beats/min; temperature \< 35.6 C \> 37.7 C. Categories with data in at least one arm group are reported.
The markedly abnormal value (MAV) criteria for 12-lead ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec). Categories with data in at least one arm group are reported.
The markedly abnormal value (MAV) criteria for continuous 12-lead Holter ECG parameters included ECG Mean Heart Rate \< 50 beats/min, \> 120 beats/min; PR Interval, Aggregate \<= 80 msec, \>= 200 msec; QRS Duration, Aggregate \<= 80 msec, \>= 180 msec; QTcB Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec); QTcF Interval, Aggregate \<= 300 msec, \>= 500 msec OR (\>= 30 msec change from baseline and \>= 450 msec). Categories with data in at least one arm group are reported.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics | EXPERIMENTAL | TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period. |
| Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics | EXPERIMENTAL | TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period. |
| Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics | EXPERIMENTAL | TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period. |
| Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics | EXPERIMENTAL | TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period. |
| Part 1 (SRD): Placebo Cohorts 1-5 | PLACEBO_COMPARATOR | TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. |
| Part 1 (SRD): Cohort 1: TAK-041 5/20 mg | EXPERIMENTAL | TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period. |
| Part 1 (SRD): Cohort 2: TAK-041 10/40 mg | EXPERIMENTAL | TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period. |
| Part 1 (SRD): Cohort 3: TAK-041 80 mg | EXPERIMENTAL | TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. |
| Part 1 (SRD): Cohort 4: TAK-041 120 mg | EXPERIMENTAL | TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. |
| Part 1 (SRD): Cohort 5: TAK-041 160 mg | EXPERIMENTAL | TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. |
| Part 2 (MRD): Placebo Cohorts 1-4 | PLACEBO_COMPARATOR | TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period. |
| Part 2 (MRD): Cohort 1: TAK-041 40/20 mg | EXPERIMENTAL | TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period. |
| Part 2 (MRD): Cohort 2: TAK-041 80/40 mg | EXPERIMENTAL | TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period. |
| Part 2 (MRD): Cohort 3: TAK-041 120/60 mg | EXPERIMENTAL | TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period. |
| Part 2 (MRD): Cohort 4: TAK-041 160/80 mg | EXPERIMENTAL | TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period. |
| Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A | EXPERIMENTAL | TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1. |
| Part 3: RBA/Food Effect: Regimen B | EXPERIMENTAL | TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2. |
| Part 4: MRD: Placebo | PLACEBO_COMPARATOR | TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia |
| Part 4: MRD: TAK-041 160/80 mg | EXPERIMENTAL | TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia. |
| Name | Type | Description |
|---|---|---|
| TAK-041 | DRUG | TAK-041 suspension |
| Placebo | DRUG | TAK-041 placebo-matching suspension |
| Second Generation Antipsychotics (SGA) | DRUG | Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone. |
| TAK-041 Placebo | DRUG | TAK-041 placebo-matching suspension or tablet. |
Inclusion Criteria: 1. Is on a stable dose of antipsychotics for at least 2 months as documented by medical history and assessed by site staff (other than those on the excluded medication list). 2. Meets schizophrenia criteria as defined by the Diagnostic and Statistical Manual of Mental Disorders ...
TAK-041 is an investigational small molecule being studied for use in stable schizophrenia and in healthy volunteers. It is being developed by Neurocrine Biosciences, Inc. (NBIX) as a potential treatment for psychiatric conditions, with clinical trials conducted in the United States and the United Kingdom.
TAK-041 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NBIX. The drug is an investigational small molecule in the psychiatry therapeutic area, currently in clinical development for stable schizophrenia.
TAK-041 is in Phase 1 clinical development. A Phase 1 first-in-human study has been completed, and a Phase 2 proof of activity study in stable schizophrenia has also been completed. The drug remains investigational and is not yet approved by regulatory authorities.
TAK-041 has been studied in two completed clinical trials. NCT02748694 was a Phase 1 first-in-human safety, tolerability, and pharmacokinetics study in healthy volunteers and schizophrenia patients. NCT03319953 was a Phase 2 randomized, double-blind, placebo-controlled proof of activity study in stable schizophrenia.
No alternative names for TAK-041 have been disclosed. The drug is identified solely by its code name TAK-041 in clinical trial registries and by its developer, Neurocrine Biosciences, Inc.